Genito-urinary Cancer

P2, N=32, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Feb 2027 | Trial primary completion date: Jan 2026 --> Feb 2027

P2, N=150, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Jul 2027 --> Jun 2028 | Trial primary completion date: Apr 2027 --> Jun 2028

P3, N=496, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting | N=804 --> 496

P=N/A, N=24, Completed, Icahn School of Medicine at Mount Sinai | Recruiting --> Completed

P2, N=50, Not yet recruiting, The University of Texas Health Science Center at San Antonio | Initiation date: Nov 2024 --> Jun 2025

Importantly, the pharmacological inhibition of TET enzymes and supplementation with S-adenosyl methionine were found to effectively suppress AR-independent prostate cancer growth. These insights shed light on the mechanism driving AR-independent lineage plasticity and propose a potential therapeutic strategy by targeting DNA hypomethylation in AR-independent CRPC.

No abstract available

P=N/A, N=589, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=874 --> 589 | Initiation date: Feb 2018 --> Jun 2018

P=N/A, N=0, Available, Agenus Inc.

P3, N=405, Completed, pharmaand GmbH | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Aug 2024

P=N/A, N=50, Not yet recruiting, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

P2, N=6, Terminated, SWOG Cancer Research Network | N=196 --> 6 | Trial completion date: Apr 2029 --> Jun 2024 | Suspended --> Terminated; inability to accrue sufficient patients

These findings reveal the prognostic importance of FAM in PCa, providing novel insights into prognosis and potential therapeutic targets for PCa management.

These findings were validated by gene expression profiling from the Gene Expression Omnibus (GEO) database, confirming a significant GRB7 downregulation in KICH and KIRC and an upregulation in PAAD compared to normal samples.  GRB7 shows potential as a biomarker in both diagnosing and predicting outcomes for various cancers. It may serve as a diagnostic marker for KICH, a prognostic marker for PAAD, and both a diagnostic and prognostic marker for KIRC, making GRB7 a target for future research and therapeutic approaches in oncology.

The here data reported can lay the foundation for predicting a poor prognosis for the studied prostate cancer, as well as the possibility of targeted therapies based on the modulation of hypoxia, ROS, and the anti-cancer immune response.

YWHAG upregulates TMOD3 expression, leading to the activation of ERK1/2 phosphorylation in the MAPK pathway, thereby promoting the invasion and metastasis of bladder cancer cells.

Notably, SMAD6 mRNA colocalized less with YTHDC1 in tumoral tissues than in paratumoral tissues, indicating disrupted binding during cancer progression. Our findings establish YTHDC1-dependent m6A reading as a critical epitranscriptomic mechanism regulating bladder cancer invasiveness and provide a paradigm for the epitranscriptomic deregulation of cancer-associated networks.

We demonstrated the advantage of IO-TKI combination therapy compared to TKI monotherapy in real-world clinical settings. However, in IMDC favorable patients PFS and OS did not significantly differ to TKI monotherapy. This may indicate the need for caution when selecting treatment options for IMDC favorable-risk patients.

Cuproptosis-related lncRNAs FOXD2-AS1, MINCR, LINC02154 show promise for the prediction of patient response (CB vs. PD) in ICI-based therapeutic schemes in patients with mccRCC.

Our findings suggest that SLC15A2 serves as a promising prognostic biomarker in PCa, enabling accurate risk stratification for BCR. This insight may contribute to the advancement of personalized treatment strategies for PCa.

In conclusion, HOXA3 transcriptionally activates USP15 expression, up-regulated USP15 facilitates the deubiquitination of SQSTM1 in RCC. This process on the one hand suppresses autophagy, on the other hand increases M2-type macrophage polarization through stimulating the secretion of CCL2.

From an application standpoint, a TLS-specific gene signature is developed that effectively predicts outcomes in MIBC and other cancers. This study highlights the prognostic potential of TLS in MIBC and reveals immune mechanisms, offering insights for personalized treatment strategies.

G-CSF expression in TCs and SCs may play a crucial role in UTUC tumor progression. Notably, stromal G-CSF expression showed significant prognostic value, even when compared to major clinicopathological factors, suggesting that the evaluation of G-CSF expression may contribute to clinical decision-making in patients with UTUC.

In conclusion, EO-ACs, particularly thymol and carvacrol, effectively reduced cell viability, and triggered caspase-dependent apoptosis in both MCF-7 and T-24 cell lines. These findings categorically underscore EO-ACs as promising active compounds for anticancer therapy, warranting further in-depth exploration through in vivo studies.

Selective targeting of FGFR3 hotspot mutations with tyrosine kinase inhibitors (e.g., erdafitinib) is approved for mUC and requires FGFR3 mutational testing...Encompassing 1222 cases, our study is a large-scale validation of a model prescreening FGFR3 mutations for MIBC and mUC patients. In this work, we demonstrate that our model achieves high sensitivity (>93%) on advanced and metastatic cases while reducing molecular testing by 40% on average, thereby offering a cost-effective and rapid pre-screening tool for identifying patients eligible for FGFR3 targeted therapies.

Rimiducid increased circulating inflammatory cytokines/chemokines consistent with GoCAR-T® cell activation. These results suggest that pharmacological activation of GoCAR-T® cells is feasible and may offer a promising avenue to control chimeric antigen receptor-T cell activity with continued dose-optimization to improve tolerability.

In this exploratory analysis, efficacy outcomes with talazoparib plus enzalutamide in Japanese patients in TALAPRO-2 were consistent with those in the overall all-comers population. The safety profile and pharmacokinetics of the combination were similar between Japanese patients and the overall all-comers population.

Finally, a network map based on LINC00565 was constructed and we found that the expression of miR-143-5p and miR-4516 were significantly correlated with LINC00565 in MIBC. Our findings indicated that the constructed 3-lncRNA panel in serum showed favorable diagnostic capacity and might serve as promising non-invasive biomarkers in the early diagnosis of MIBC.

Our findings reveal a potential mechanism by which SPP1-CD44 signaling mediates tumor-immune cell interactions leading to ICI resistance, providing a theoretical basis for targeting and disrupting this signaling to overcome primary resistance in RCC.

Upregulation of GSTP1 mediated by chimeric TFE3 promotes TFE3-tRCC progression by targeting JNK signaling pathway, which underscore the potential of GSTP1 as a promising therapeutic target for TFE3-tRCC.

PCA3 had a better diagnosis accuracy than tPSA, %fPSA and PSAD. PCA3 was a significantly independent predictor for risk stratification, suggesting that PCA3 could provide incremental value to reduce unnecessary prostate biopsies.

The identification of B cells and CD8 + T cells as key immune components, along with specific amino acids, suggests that a combination of targeted immune therapies and dietary interventions could provide a multifaceted approach to KICH treatment. Given the limited understanding of KICH pathogenesis, our analysis has unveiled new theoretical insights and potential clinical significances for KICH, expected to broaden the research horizon in this field.

Moreover, under high-fat conditions, the tumors are more sensitive to HA@CD36i-TR@siSCD1 treatment, almost no accumulation of lipid droplets is observed in HA@CD36i-TR@siSCD1-treated tumors, with enhanced antitumor immunity. Hence, this study provides a new treatment option for refractory PCa patients, especially those with a high-fat diet.

The findings revealed no clear link between CD147 expression and tumor grade, diverging from prior studies that associate CD147 with advanced tumor stages. The nonsignificant results may be attributed to the small sample size, emphasizing the need for future research with larger, more diverse cohorts, advanced molecular techniques, and functional studies to better elucidate the role of CD147 in prostate cancer pathogenesis and its potential as a therapeutic target.

Additionally, the transcription factor MAFG was found to transcriptionally activate MAFG-DT in PCa. This study confirms the oncogenic role of MAFG/MAFG-DT/miR-24-3p/Wnt/β-catenin in PCa, which suggests that MAFG-DT could serve as a potential therapeutic target for PCa.

Patients in the TDERS high group were resistant to ICIs, while mercaptopurine might function as a promising agent for those patients...Finally, PLOD2, which is highly expressed in fibro- and epi‑tissue, could be a potential therapeutic target for ccRCC patients since inhibiting PLOD2 altered the malignant phenotype of ccRCC in vitro. As a novel, non-invasive, and repeatable monitoring tool, the TDERS could work as a robust risk stratification system for patients with ccRCC and precisely inform treatment decisions about ICI therapy.

:Although ARTAs did not show any significant increase in incidence of cardiac-related adverse events, there is an increased risk of hypertension especially with the use of enzalutamide. With this knowledge, closer blood pressure monitoring is needed for patients started on ARTA, especially enzalutamide.

A collaborative evaluation by the multidisciplinary team involving urological surgeons, pathologists, and radiologists was crucial in reaching the final diagnosis of metastatic prostate adenocarcinoma to the testis. This case emphasizes the importance of maintaining a high suspicion for metastasis in prostate cancer patients, even when clinical or radiological findings are not prominent, as the diagnostic approach may not always follow a predictable course.

P1, N=243, Recruiting, Iambic Therapeutics, Inc | Trial primary completion date: Apr 2028 --> Mar 2027

Experimentally, T cell membrane-biomimetic NPs loaded with the AURKA inhibitor Alisertib and chemotherapy drug DTX were synthesized and characterized by dynamic light scattering and transmission electron microscopy, showing good stability and uniformity (average diameter: 158 nm)...In vivo, CM-AMS@AD NPs accumulated in tumor tissues, significantly slowed tumor growth, decreased proliferation, increased apoptosis, and improved the immune environment, enhancing dendritic cell (DC) maturation and increasing CD8 + /CD4 + ratios. These findings suggest that CM-AMS@AD NPs offer a promising triple-combination therapy for CRPC, integrating photothermal, chemotherapy, and immunotherapy, with significant potential for future clinical applications.

Overall, this research affirms the crucial function of RUNX2 as a key transcription factor to promoting glutamine and cancer development through modulation of SLC7A6. Targeting RUNX2 could represent a promising therapeutic approach for addressing aberrant glutamine metabolism in bladder cancer.

We have identified novel NETs-related clusters and developed a NETs-related model for PCa that has excellent predictive performance for predicting biochemical recurrences as well as chemotherapy efficacy.